RVMD - Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.
Details of the planned presentations are listed below:
Revolution Medicines Oral Presentations:
| Title: |
| Discovery of RMC-6291, a tri-complex KRAS G12C (ON) inhibitor |
| Presenter: |
| Jim Cregg, Ph.D. |
| Abstract Number: |
| ND07 |
| Session: |
| New Drugs on the Horizon: Part 2 |
| Date/Time: |
| 3:45 – 4:00 p.m. Eastern on April 16, 2023 |
| Title: |
| RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRAS G12D (ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models |
| Presenter: |
| Marie Menard, Ph.D. |
| Abstract Number: |
| 3475 |
| Session: |
| Immune Checkpoints at Tumor Beds |
| Date/Time: |
| 3:37 – 3:52 p.m. Eastern on April 17, 2023 |
Revolution Medicines Poster Presentations:
| Title: |
| RMC-9805, a first-in-class, mutant-selective, covalent and oral KRAS G12D (ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRAS G12D cancers |
| Presenter: |
| Lingyan Jiang, Ph.D. |
| Abstract Number: |
| 526/26 |
| Session: |
| Novel Antitumor Agents 2 |
| Date/Time: |
| 1:30 – 5:00 p.m. Eastern on April 16, 2023 |
| Title: |
| RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRAS Q61H (ON) inhibitor that drives tumor regression in preclinical models and validates KRAS Q61H as a therapeutic target |
| Presenter: |
| Yu C. Yang, Ph.D. |
| Abstract Number: |
| 1598/21 |
| Session: |
| New Therapeutic Targeted Agents |
| Date/Time: |
| 9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023 |
Collaborator Oral Presentation:
| Title: |
| Combining KRAS G12C (ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer |
| Abstract Number: |
| 5733 |
| Session: |
| New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling |
| Presentation Time: |
| 2:37 – 2:52 p.m. Eastern on April 18, 2023 |
Collaborator Poster Presentations:
| Title: |
| Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression |
| Abstract Number: |
| LB015/7 |
| Session: |
| Late-Breaking Research: Experimental and Molecular Therapeutics 1 |
| Presentation Time: |
| 1:30 – 5:00 p.m. Eastern on April 16, 2023 |
| Title: |
| Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma |
| Abstract Number: |
| 1725/22 |
| Session: |
| Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2 |
| Date/Time: |
| 9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023 |
| Title: |
| Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1 |
| Abstract Number: |
| 4859/2 |
| Session: |
| Anticancer Approaches Targeting Signal Transduction Pathways |
| Presentation Time: |
| 1:30 – 5:00 p.m. Eastern on April 18, 2023 |
Additional information on the AACR Annual Meeting 2023 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2023/
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RAS MULTI ) and RMC-6291(KRAS G12C ) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRAS G12D ) and RMC-0708 (KRAS Q61H ), both of which are currently in IND-enabling development, RMC-8839 (KRAS G13C ), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
Contacts:For Investors & Media:Erin Graves650-779-0136egraves@revmed.com